BioSpace News Archive

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced preliminary revenue results for the second quarter ended June 30, 2022.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Products and services offered by players in the global dental insurance market i.e. the dental insurance services is a health insurance specifically designed for the purpose of dental care.

Bioresorbable scaffolds have witnessed massive application prospects in cardiology, arising out of need to improve the prognosis of patients with coronary heart disease.

Wilmington, Delaware, United States, Transparency Market Research Inc.: A recent study showed that nearly 20% people across the world are sleep-deprived, and this means that there will be more people in the coming years who could be victims of acute or chronic insomnia.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Rising developments in the medical therapy and disease prevention field are estimated to help the global vaccines market to expand at a CAGR of 6% during the forecast period of 2017 to 2025.

Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s Biologics License Application and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange.

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.

Kamada Ltd. announced that it has secured an $11.4 million agreement to supply VARIZIG® to an undisclosed international organization, operating principally in Latin America.